{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T22:35:31Z","timestamp":1785537331621,"version":"3.56.0"},"reference-count":187,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T00:00:00Z","timestamp":1729641600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82003985"],"award-info":[{"award-number":["82003985"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["JLPZGF-2020-107"],"award-info":[{"award-number":["JLPZGF-2020-107"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["202310199001"],"award-info":[{"award-number":["202310199001"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["202310199051X"],"award-info":[{"award-number":["202310199051X"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["20210204013YY"],"award-info":[{"award-number":["20210204013YY"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["20230401062YY"],"award-info":[{"award-number":["20230401062YY"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["20230204019YY"],"award-info":[{"award-number":["20230204019YY"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["20230401075YY"],"award-info":[{"award-number":["20230401075YY"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["2023C027-3"],"award-info":[{"award-number":["2023C027-3"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["2022JP06"],"award-info":[{"award-number":["2022JP06"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Drug Administration project of Jilin province","award":["82003985"],"award-info":[{"award-number":["82003985"]}]},{"name":"Drug Administration project of Jilin province","award":["JLPZGF-2020-107"],"award-info":[{"award-number":["JLPZGF-2020-107"]}]},{"name":"Drug Administration project of Jilin province","award":["202310199001"],"award-info":[{"award-number":["202310199001"]}]},{"name":"Drug Administration project of Jilin province","award":["202310199051X"],"award-info":[{"award-number":["202310199051X"]}]},{"name":"Drug Administration project of Jilin province","award":["20210204013YY"],"award-info":[{"award-number":["20210204013YY"]}]},{"name":"Drug Administration project of Jilin province","award":["20230401062YY"],"award-info":[{"award-number":["20230401062YY"]}]},{"name":"Drug Administration project of Jilin province","award":["20230204019YY"],"award-info":[{"award-number":["20230204019YY"]}]},{"name":"Drug Administration project of Jilin province","award":["20230401075YY"],"award-info":[{"award-number":["20230401075YY"]}]},{"name":"Drug Administration project of Jilin province","award":["2023C027-3"],"award-info":[{"award-number":["2023C027-3"]}]},{"name":"Drug Administration project of Jilin province","award":["2022JP06"],"award-info":[{"award-number":["2022JP06"]}]},{"name":"National College Students\u2019 innovation and entrepreneurship training program","award":["82003985"],"award-info":[{"award-number":["82003985"]}]},{"name":"National College Students\u2019 innovation and entrepreneurship training program","award":["JLPZGF-2020-107"],"award-info":[{"award-number":["JLPZGF-2020-107"]}]},{"name":"National College Students\u2019 innovation and entrepreneurship training program","award":["202310199001"],"award-info":[{"award-number":["202310199001"]}]},{"name":"National College Students\u2019 innovation and entrepreneurship training program","award":["202310199051X"],"award-info":[{"award-number":["202310199051X"]}]},{"name":"National College Students\u2019 innovation and entrepreneurship training program","award":["20210204013YY"],"award-info":[{"award-number":["20210204013YY"]}]},{"name":"National College Students\u2019 innovation and entrepreneurship training program","award":["20230401062YY"],"award-info":[{"award-number":["20230401062YY"]}]},{"name":"National College Students\u2019 innovation and entrepreneurship training program","award":["20230204019YY"],"award-info":[{"award-number":["20230204019YY"]}]},{"name":"National College Students\u2019 innovation and entrepreneurship training program","award":["20230401075YY"],"award-info":[{"award-number":["20230401075YY"]}]},{"name":"National College Students\u2019 innovation and entrepreneurship training program","award":["2023C027-3"],"award-info":[{"award-number":["2023C027-3"]}]},{"name":"National College Students\u2019 innovation and entrepreneurship training program","award":["2022JP06"],"award-info":[{"award-number":["2022JP06"]}]},{"name":"Jilin Province Science and Technology Development Project in China","award":["82003985"],"award-info":[{"award-number":["82003985"]}]},{"name":"Jilin Province Science and Technology Development Project in China","award":["JLPZGF-2020-107"],"award-info":[{"award-number":["JLPZGF-2020-107"]}]},{"name":"Jilin Province Science and Technology Development Project in China","award":["202310199001"],"award-info":[{"award-number":["202310199001"]}]},{"name":"Jilin Province Science and Technology Development Project in China","award":["202310199051X"],"award-info":[{"award-number":["202310199051X"]}]},{"name":"Jilin Province Science and Technology Development Project in China","award":["20210204013YY"],"award-info":[{"award-number":["20210204013YY"]}]},{"name":"Jilin Province Science and Technology Development Project in China","award":["20230401062YY"],"award-info":[{"award-number":["20230401062YY"]}]},{"name":"Jilin Province Science and Technology Development Project in China","award":["20230204019YY"],"award-info":[{"award-number":["20230204019YY"]}]},{"name":"Jilin Province Science and Technology Development Project in China","award":["20230401075YY"],"award-info":[{"award-number":["20230401075YY"]}]},{"name":"Jilin Province Science and Technology Development Project in China","award":["2023C027-3"],"award-info":[{"award-number":["2023C027-3"]}]},{"name":"Jilin Province Science and Technology Development Project in China","award":["2022JP06"],"award-info":[{"award-number":["2022JP06"]}]},{"name":"Jilin Provincial Development and Reform Commission program","award":["82003985"],"award-info":[{"award-number":["82003985"]}]},{"name":"Jilin Provincial Development and Reform Commission program","award":["JLPZGF-2020-107"],"award-info":[{"award-number":["JLPZGF-2020-107"]}]},{"name":"Jilin Provincial Development and Reform Commission program","award":["202310199001"],"award-info":[{"award-number":["202310199001"]}]},{"name":"Jilin Provincial Development and Reform Commission program","award":["202310199051X"],"award-info":[{"award-number":["202310199051X"]}]},{"name":"Jilin Provincial Development and Reform Commission program","award":["20210204013YY"],"award-info":[{"award-number":["20210204013YY"]}]},{"name":"Jilin Provincial Development and Reform Commission program","award":["20230401062YY"],"award-info":[{"award-number":["20230401062YY"]}]},{"name":"Jilin Provincial Development and Reform Commission program","award":["20230204019YY"],"award-info":[{"award-number":["20230204019YY"]}]},{"name":"Jilin Provincial Development and Reform Commission program","award":["20230401075YY"],"award-info":[{"award-number":["20230401075YY"]}]},{"name":"Jilin Provincial Development and Reform Commission program","award":["2023C027-3"],"award-info":[{"award-number":["2023C027-3"]}]},{"name":"Jilin Provincial Development and Reform Commission program","award":["2022JP06"],"award-info":[{"award-number":["2022JP06"]}]},{"name":"Changchun University of Chinese Medicine postgraduate training innovation demonstration project","award":["82003985"],"award-info":[{"award-number":["82003985"]}]},{"name":"Changchun University of Chinese Medicine postgraduate training innovation demonstration project","award":["JLPZGF-2020-107"],"award-info":[{"award-number":["JLPZGF-2020-107"]}]},{"name":"Changchun University of Chinese Medicine postgraduate training innovation demonstration project","award":["202310199001"],"award-info":[{"award-number":["202310199001"]}]},{"name":"Changchun University of Chinese Medicine postgraduate training innovation demonstration project","award":["202310199051X"],"award-info":[{"award-number":["202310199051X"]}]},{"name":"Changchun University of Chinese Medicine postgraduate training innovation demonstration project","award":["20210204013YY"],"award-info":[{"award-number":["20210204013YY"]}]},{"name":"Changchun University of Chinese Medicine postgraduate training innovation demonstration project","award":["20230401062YY"],"award-info":[{"award-number":["20230401062YY"]}]},{"name":"Changchun University of Chinese Medicine postgraduate training innovation demonstration project","award":["20230204019YY"],"award-info":[{"award-number":["20230204019YY"]}]},{"name":"Changchun University of Chinese Medicine postgraduate training innovation demonstration project","award":["20230401075YY"],"award-info":[{"award-number":["20230401075YY"]}]},{"name":"Changchun University of Chinese Medicine postgraduate training innovation demonstration project","award":["2023C027-3"],"award-info":[{"award-number":["2023C027-3"]}]},{"name":"Changchun University of Chinese Medicine postgraduate training innovation demonstration project","award":["2022JP06"],"award-info":[{"award-number":["2022JP06"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceutics"],"abstract":"<jats:p>Diabetes is a global disease that can lead to a range of complications. Currently, the treatment of type 2 diabetes focuses on oral hypoglycemic drugs and insulin analogues. Studies have shown that drugs such as oral metformin are useful in the treatment of diabetes but can limit the liver\u2019s ability to release sugar. The development of glucose-lowering peptides has provided new options for the treatment of type 2 diabetes. Peptide drugs have low oral utilization due to their easy degradation, short half-life, and difficulty passing through the intestinal mucosa. Therefore, improving the oral utilization of peptide drugs remains an urgent problem. This paper reviews the research progress of peptide drugs in the treatment of diabetes mellitus and proposes that different types of nano-formulation carriers, such as liposomes, self-emulsifying drug delivery systems, and polymer particles, should be combined with peptide drugs for oral administration to improve their absorption in the gastrointestinal tract.<\/jats:p>","DOI":"10.3390\/pharmaceutics16111353","type":"journal-article","created":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T09:07:04Z","timestamp":1729674424000},"page":"1353","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Research Progress on Peptide Drugs for Type 2 Diabetes and the Possibility of Oral Administration"],"prefix":"10.3390","volume":"16","author":[{"given":"Xinxin","family":"Yang","sequence":"first","affiliation":[{"name":"School of Pharmacy, Changchun University of Chinese Medicine, Changchun 130117, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruiting","family":"Lin","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Changchun University of Chinese Medicine, Changchun 130117, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changzhuo","family":"Feng","sequence":"additional","affiliation":[{"name":"College of Traditional Chinese Medicine, Changchun University of Chinese Medicine, Changchun 130117, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiyuan","family":"Kang","sequence":"additional","affiliation":[{"name":"College of Traditional Chinese Medicine, Changchun University of Chinese Medicine, Changchun 130117, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Yu","sequence":"additional","affiliation":[{"name":"College of Traditional Chinese Medicine, Changchun University of Chinese Medicine, Changchun 130117, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongzhi","family":"Deng","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Changchun University of Chinese Medicine, Changchun 130117, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3969-5474","authenticated-orcid":false,"given":"Ye","family":"Jin","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Changchun University of Chinese Medicine, Changchun 130117, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,10,23]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Jin, Q., and Ma, R.C.W. (2021). Metabolomics in Diabetes and Diabetic Complications: Insights from Epidemiological Studies. Cells, 10.","DOI":"10.3390\/cells10112832"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1055\/a-0984-5696","article-title":"Therapy of Type 1 Diabetes","volume":"127","author":"Haak","year":"2019","journal-title":"Exp. Clin. Endocrinol. Diabetes"},{"key":"ref_3","first-page":"442","article-title":"Type 2 Diabetes and its Impact on the Immune System","volume":"16","author":"Berbudi","year":"2020","journal-title":"Curr. Diabetes Rev."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.maturitas.2018.03.013","article-title":"Hypertension in patients with type 2 diabetes mellitus: Targets and management","volume":"112","author":"Pavlou","year":"2018","journal-title":"Maturitas"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Alsaadon, H., Afroz, A., Karim, A., Habib, S.H., Alramadan, M.J., Billah, B., and Shetty, A.N. (2022). Hypertension and its related factors among patients with type 2 diabetes mellitus\u2014A multi-hospital study in Bangladesh. BMC Public Health, 22.","DOI":"10.1186\/s12889-022-12509-1"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.tips.2020.11.002","article-title":"Developing Insulin Delivery Devices with Glucose Responsiveness","volume":"42","author":"Wang","year":"2021","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1111\/dme.13895","article-title":"Ethnicity and Type 2 diabetes in the UK","volume":"36","author":"Goff","year":"2019","journal-title":"Diabet. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"61","DOI":"10.7748\/ns.2021.e11709","article-title":"Diabetes mellitus: An overview of the types, symptoms, complications and management","volume":"37","author":"Cloete","year":"2021","journal-title":"Nurs. Stand."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.ijpharm.2012.03.056","article-title":"Oral delivery of therapeutic protein\/peptide for diabetes\u2014Future perspectives","volume":"440","author":"Rekha","year":"2013","journal-title":"Int. J. Pharmaceut."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.ejpb.2021.02.008","article-title":"Oral Drug Delivery: Conventional to Long Acting New-Age Designs","volume":"162","author":"Bhutani","year":"2021","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.addr.2016.04.001","article-title":"Lipid-based nanocarriers for oral peptide delivery","volume":"106","author":"Niu","year":"2016","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1111\/dom.13022","article-title":"Variability in and predictors of glycaemic responses after 24 weeks of treatment with exenatide twice daily and exenatide once weekly","volume":"19","author":"Shaw","year":"2017","journal-title":"Diabetes Obes. Metab."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s12933-023-01845-0","article-title":"Liraglutide reduces plasma dihydroceramide levels in patients with type 2 diabetes","volume":"22","author":"Denimal","year":"2023","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1111\/dom.14163","article-title":"Efficacy and safety of polyethylene glycol loxenatide as add-on to metformin in patients with type 2 diabetes: A multicentre, randomized, double-blind, placebo-controlled, phase 3b trial","volume":"22","author":"Gao","year":"2020","journal-title":"Diabetes Obes. Metab."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"438","DOI":"10.2337\/db18-438-P","article-title":"Liraglutide Effects in Insulin-Treated Patients in LEADER","volume":"67","author":"Tack","year":"2018","journal-title":"Diabetes"},{"key":"ref_16","first-page":"e13483","article-title":"The efficacy and safety of beinaglutide alone or in combination with insulin glargine in Chinese patients with type 2 diabetes mellitus who are inadequately controlled with oral antihyperglycemic therapy: A multicenter, open-label, randomized trial","volume":"16","author":"Xiangyang","year":"2023","journal-title":"J. Diabetes"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.2337\/db20-1428-P","article-title":"1428-P: Cardiovascular Outcomes with Dulaglutide vs. Liraglutide","volume":"69","author":"Bowe","year":"2020","journal-title":"Diabetes"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1111\/dom.15058","article-title":"Effects of oral semaglutide on cardiovascular outcomes in individuals with type 2 diabetes and established atherosclerotic cardiovascular disease and\/or chronic kidney disease: Design and baseline characteristics of SOUL, a randomized trial","volume":"25","author":"McGuire","year":"2023","journal-title":"Diabetes Obes. Metab."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1007\/s00125-022-05715-4","article-title":"Management of type 2 diabetes with the dual GIP\/GLP-1 receptor agonist tirzepatide: A systematic review and meta-analysis","volume":"65","author":"Karagiannis","year":"2022","journal-title":"Diabetologia"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.cmet.2018.03.001","article-title":"Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1","volume":"27","author":"Drucker","year":"2018","journal-title":"Cell Metab."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.molmet.2019.09.010","article-title":"Glucagon-like peptide 1 (GLP-1)","volume":"30","author":"Finan","year":"2019","journal-title":"Mol. Metab."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/0167-0115(95)00167-0","article-title":"Proglucagon processing in islet and intestinal cell lines","volume":"62","author":"Tucker","year":"1996","journal-title":"Regul. Pept."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/jdi.12478","article-title":"Mechanisms underlying glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 secretion","volume":"7","author":"Reimann","year":"2016","journal-title":"J. Diabetes Investig."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/j.coph.2013.08.013","article-title":"Molecular mechanisms of incretin hormone secretion","volume":"13","author":"Ezcurra","year":"2013","journal-title":"Curr. Opin. Pharmacol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/j.yexcr.2011.01.010","article-title":"GLP-1 for type 2 diabetes","volume":"317","year":"2011","journal-title":"Exp. Cell Res."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"101102","DOI":"10.1016\/j.molmet.2020.101102","article-title":"GLP-1 receptor agonists in the treatment of type 2 diabetes\u2014State-of-the-art","volume":"46","author":"Nauck","year":"2020","journal-title":"Mol. Metab."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Vasu, S., Moffett, R.C., Thorens, B., and Flatt, P.R. (2014). Role of endogenous GLP-1 and GIP in beta cell compensatory responses to insulin resistance and cellular stress. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0101005"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.cmet.2010.04.007","article-title":"GLP-1 inhibits and adrenaline stimulates glucagon release by differential modulation of N- and L-type Ca2+ channel-dependent exocytosis","volume":"11","author":"Salehi","year":"2010","journal-title":"Cell Metab."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"4217","DOI":"10.1172\/JCI97233","article-title":"Discovery, characterization, and clinical development of the glucagon-like peptides","volume":"127","author":"Drucker","year":"2017","journal-title":"J. Clin. Investig."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1210\/en.2018-00004","article-title":"GLP-1 Receptor Expression Within the Human Heart","volume":"159","author":"Baggio","year":"2018","journal-title":"Endocrinology"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.regpep.2007.10.001","article-title":"Protective effects of GLP-1 analogues exendin-4 and GLP-1(9-36) amide against ischemia-reperfusion injury in rat heart","volume":"146","author":"Sonne","year":"2007","journal-title":"Regul. Pept."},{"key":"ref_32","first-page":"659","article-title":"Glucagon-like peptide-1 (GLP-1) receptor agonists and their cardiovascular benefits\u2014The role of the GLP-1 receptor","volume":"179","author":"Keppeler","year":"2021","journal-title":"Br. J. Pharmacol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.neuint.2019.04.010","article-title":"GLP-1: Molecular mechanisms and outcomes of a complex signaling system","volume":"128","author":"Smith","year":"2019","journal-title":"Neurochem. Int."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1152\/physrev.00034.2006","article-title":"The physiology of glucagon-like peptide 1","volume":"87","author":"Holst","year":"2007","journal-title":"Physiol. Rev."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1111\/bph.15638","article-title":"Brain GLP-1 and the regulation of food intake: GLP-1 action in the brain and its implications for GLP-1 receptor agonists in obesity treatment","volume":"179","author":"Trapp","year":"2021","journal-title":"Br. J. Pharmacol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1007\/s00125-016-3896-5","article-title":"GLP-1 receptor agonist promotes brown remodelling in mouse white adipose tissue through SIRT1","volume":"59","author":"Xu","year":"2016","journal-title":"Diabetologia"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0167-0115(98)00010-X","article-title":"Sympathetic pathways mediate GLP-1 actions in the gastrointestinal tract of the rat","volume":"74","author":"Giralt","year":"1998","journal-title":"Regul. Pept."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/S2213-8587(19)30065-8","article-title":"GLP-1 and the renin-angiotensin-aldosterone system","volume":"7","author":"Babkowski","year":"2019","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1007\/s10157-024-02516-4","article-title":"One anastomosis gastric bypass ameliorates diabetic nephropathy via regulating the GLP-1-mediated Sirt1\/AMPK\/PGC1\u03b1 pathway","volume":"28","author":"Han","year":"2024","journal-title":"Clin. Exp. Nephrol."},{"key":"ref_40","first-page":"2921","article-title":"The Discovery and Development of Glucagon-Like Peptide-1 Receptor Agonists","volume":"30","author":"Niu","year":"2023","journal-title":"Curr. Med. Chem."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1038\/nrd1828","article-title":"Exenatide","volume":"4","author":"Davidson","year":"2005","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1111\/dom.14067","article-title":"Exenatide once weekly decreases urinary albumin excretion in patients with type 2 diabetes and elevated albuminuria: Pooled analysis of randomized active controlled clinical trials","volume":"22","author":"Raalte","year":"2020","journal-title":"Diabetes Obes. Metab."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Wang, M.-J., Cai, X., Liang, R.-Y., Zhang, E.-M., Liang, X.-Q., Liang, H., Fu, C., Zhou, A.-D., Shi, Y., and Xu, F. (2023). SIRT1-dependent deacetylation of Txnip H3K9ac is critical for exenatide-improved diabetic kidney disease. Biomed. Pharmacother., 167.","DOI":"10.1016\/j.biopha.2023.115515"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.1111\/dom.14451","article-title":"Comparative efficacy of glucose-lowering medications on body weight and blood pressure in patients with type 2 diabetes: A systematic review and network meta-analysis","volume":"23","author":"Tsapas","year":"2021","journal-title":"Diabetes Obes. Metab."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1016\/S0140-6736(08)61206-4","article-title":"Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: A randomised, open-label, non-inferiority study","volume":"372","author":"Drucker","year":"2008","journal-title":"Lancet"},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Lv, Q., Yang, Y., Lv, Y., Wu, Q., Hou, X., Li, L., Ye, X., Yang, C., and Wang, S. (2024). Long-term effects of different hypoglycemic drugs on carotid intima-media thickness progression: A systematic review and network meta-analysis. Front. Endocrinol., 15.","DOI":"10.3389\/fendo.2024.1403606"},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Zhou, Q., Hao, G., Xie, W., Chen, B., Lu, W., Wang, G., Zhong, R., Chen, J., Ye, J., and Shen, J. (2024). Exenatide reduces atrial fibrillation susceptibility by inhibiting hKv1.5 and hNav1.5 channels. J. Biol. Chem., 300.","DOI":"10.1016\/j.jbc.2024.107294"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1089\/dia.2011.0050","article-title":"Encapsulation of exenatide in poly-(D,L-lactide-co-glycolide) microspheres produced an investigational long-acting once-weekly formulation for type 2 diabetes","volume":"13","author":"DeYoung","year":"2011","journal-title":"Diabetes Technol. Ther."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"e1801509","DOI":"10.1002\/adhm.201801509","article-title":"Molecular and Materials Engineering for Delivery of Peptide Drugs to Treat Type 2 Diabetes","volume":"8","author":"Varanko","year":"2019","journal-title":"Adv. Healthc. Mater."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Cai, H., Chen, Q., Duan, Y., Zhao, Y., and Zhang, X. (2023). Short-term effect of polyethylene glycol loxenatide on weight loss in overweight or obese patients with type 2 diabetes: An open-label, parallel-arm, randomized, metformin-controlled trial. Front. Endocrinol., 14.","DOI":"10.3389\/fendo.2023.1106868"},{"key":"ref_51","first-page":"1","article-title":"Polyethylene Glycol Loxenatide (PEX-168) Reduces Body Weight and Blood Glucose in Simple Obese Mice","volume":"2021","author":"Wu","year":"2021","journal-title":"Int. J. Endocrinol."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Chen, F., He, L., Li, J., Yang, S., Zhang, B., Zhu, D., Wu, Z., Zhang, S., Hou, D., and Ouyang, C. (2022). Polyethylene Glycol Loxenatide Injection (GLP-1) Protects Vascular Endothelial Cell Function in Middle-Aged and Elderly Patients with Type 2 Diabetes by Regulating Gut Microbiota. Front. Mol. Biosci., 9.","DOI":"10.3389\/fmolb.2022.879294"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"e069080","DOI":"10.1136\/bmjopen-2022-069080","article-title":"Impact of polyethylene glycol loxenatide on cardiovascular outcomes in patients with type 2 diabetes: Study protocol for a multicentre, randomised, double-blind, placebo-controlled trial (BALANCE-3)","volume":"13","author":"Xie","year":"2023","journal-title":"BMJ Open"},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Yuan, J., Wang, Y., Wang, D., Yan, H., and Wang, N. (2023). Loxenatide attenuates ROS-mediated vascular endothelial progenitor cell damage and mitochondrial dysfunction via SIRT3\/Foxo3 signaling pathway. J. Biochem. Mol. Toxicol., 37.","DOI":"10.1002\/jbt.23452"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1124\/jpet.103.051987","article-title":"Glucagon-like peptide 1 receptor agonist ZP10A increases insulin mRNA expression and prevents diabetic progression in db\/db mice","volume":"307","author":"Thorkildsen","year":"2003","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1002\/dmrr.2548","article-title":"Lixisenatide as add-on to oral anti-diabetic therapy: An effective treatment for glycaemic control with body weight benefits in type 2 diabetes","volume":"30","author":"Raccah","year":"2014","journal-title":"Diabetes Metab. Res."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1111\/dom.13444","article-title":"Low Incidence of Gastrointestinal Adverse Events Over Time with a Fixed-Ratio Combination of Insulin Glargine and Lixisenatide vs Lixisenatide Alone","volume":"20","author":"Trujillo","year":"2018","journal-title":"Diabetes Obes. Metab."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s40259-013-0057-y","article-title":"Lixisenatide: A review of its use in patients with type 2 diabetes mellitus","volume":"27","author":"Scott","year":"2013","journal-title":"BioDrugs"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1007\/s40265-017-0783-4","article-title":"Insulin Glargine\/Lixisenatide: A Review in Type 2 Diabetes","volume":"77","author":"Scott","year":"2017","journal-title":"Drugs"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.2337\/dc20-0190","article-title":"Effects of Sustained Treatment with Lixisenatide on Gastric Emptying and Postprandial Glucose Metabolism in Type 2 Diabetes: A Randomized Controlled Trial","volume":"43","author":"Rayner","year":"2020","journal-title":"Diabetes Care"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1007\/s00125-017-4330-3","article-title":"The GLP-1 analogue lixisenatide decreases atherosclerosis in insulin-resistant mice by modulating macrophage phenotype","volume":"60","author":"Navarro","year":"2017","journal-title":"Diabetologia"},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Xu, L., Chen, G., Zhang, L., He, A., and Li, Y. (2023). Lixisenatide ameliorated lipopolysaccharide (LPS)-induced expression of mucin and inflammation in bronchial epithelial cells. J. Biochem. Mol. Toxicol., 38.","DOI":"10.1002\/jbt.23618"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1016\/j.bbrc.2018.11.135","article-title":"Lixisenatide enhances mitochondrial biogenesis and function through regulating the CREB\/PGC-1\u03b1 pathway","volume":"508","author":"Zhao","year":"2019","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1517\/13543784.2011.562191","article-title":"Lixisenatide for type 2 diabetes mellitus","volume":"20","author":"Christensen","year":"2011","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1111\/dom.12986","article-title":"Efficacy and safety of lixisenatide in patients with type 2 diabetes and renal impairment","volume":"19","author":"Hanefeld","year":"2017","journal-title":"Diabetes Obes. Metab."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1080\/14656566.2019.1695779","article-title":"An evaluation of liraglutide including its efficacy and safety for the treatment of obesity","volume":"21","author":"Lin","year":"2019","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1038\/nrd3148","article-title":"Liraglutide","volume":"9","author":"Drucker","year":"2010","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Vandemark, C., Nguyen, J., and Zhao, Z.-Q. (2023). Cardiovascular Protection with a Long-Acting GLP-1 Receptor Agonist Liraglutide: An Experimental Update. Molecules, 28.","DOI":"10.3390\/molecules28031369"},{"key":"ref_69","first-page":"3722","article-title":"Liraglutide repairs the infarcted heart: The role of the SIRT1\/Parkin\/mitophagy pathway","volume":"17","author":"Qiao","year":"2018","journal-title":"Mol. Med. Rep."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"170212","DOI":"10.1016\/j.peptides.2019.170212","article-title":"Liraglutide ameliorates palmitate-induced oxidative injury in islet microvascular endothelial cells through GLP-1 receptor\/PKA and GTPCH1\/eNOS signaling pathways","volume":"124","author":"Le","year":"2020","journal-title":"Peptides"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1111\/dom.14903","article-title":"Comparative effects of weight loss and incretin-based therapies on vascular endothelial function, fibrinolysis and inflammation in individuals with obesity and prediabetes: A randomized controlled trial","volume":"25","author":"Mashayekhi","year":"2022","journal-title":"Diabetes Obes. Metab."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1530\/EC-20-0294","article-title":"Liraglutide protects against high-fat diet-induced kidney injury by ameliorating apoptosis","volume":"9","author":"Liang","year":"2020","journal-title":"Endocr. Connect."},{"key":"ref_73","first-page":"1532","article-title":"Liraglutide May Reduce Diabetic Kidney Disease","volume":"318","author":"Slomski","year":"2017","journal-title":"JAMA"},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Wronka, M., Krzemi\u0144ska, J., M\u0142ynarska, E., Rysz, J., and Franczyk, B. (2023). New Insights into the Use of Liraglutide\u2014Impact on Cardiovascular Risk and Microvascular Outcomes. Biomedicines, 11.","DOI":"10.3390\/biomedicines11041159"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1056\/NEJMoa1616011","article-title":"Liraglutide and Renal Outcomes in Type 2 Diabetes","volume":"377","author":"Mann","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_76","first-page":"2849","article-title":"Liraglutide protects renal mesangial cells against hyperglycemia-mediated mitochondrial apoptosis by activating the ERK-Yap signaling pathway and upregulating Sirt3 expression","volume":"19","author":"Li","year":"2019","journal-title":"Mol. Med. Rep."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.2337\/db19-2032-P","article-title":"2032-P: The Effects of Liraglutide on Ameliorating Diabetic Kidney Disease Is via SIRT1\/TXNIP Pathway","volume":"68","author":"Liang","year":"2019","journal-title":"Diabetes"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"118966","DOI":"10.1016\/j.lfs.2020.118966","article-title":"Beinaglutide shows significantly beneficial effects in diabetes\/obesity-induced nonalcoholic steatohepatitis in ob\/ob mouse model","volume":"270","author":"Fang","year":"2021","journal-title":"Life Sci."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1002\/osp4.342","article-title":"Beinaglutide showed significant weight-loss benefit and effective glycaemic control for the treatment of type 2 diabetes in a real-world setting: A 3-month, multicentre, observational, retrospective, open-label study","volume":"5","author":"Zhang","year":"2019","journal-title":"Obes. Sci. Pract."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1055\/a-1608-0345","article-title":"Comparison of Beinaglutide Versus Metformin for Weight Loss in Overweight and Obese Non-diabetic Patients","volume":"130","author":"Gao","year":"2021","journal-title":"Exp. Clin. Endocrinol. Diabetes"},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"Wen, Q., Fang, S., Liang, Y., Tian, Y., Chen, Y., Yuan, J., and Chen, Q. (2023). Short-term effect of beinaglutide combined with metformin versus metformin alone on weight loss and metabolic profiles in obese patients with polycystic ovary syndrome: A pilot randomized trial. Front. Endocrinol., 14.","DOI":"10.3389\/fendo.2023.1156521"},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Wang, G.-Y., Wang, H.-Q., Zhang, F.-J., Jiao, A.-F., Li, Y.-Y., Zhang, J.-M., Huang, Z.-L., Gao, Y.-H., Chi, Y.-J., and Ma, C.-M. (2020). The effect of beinaglutide on visceral fat and bodyweight in obese type 2 diabetic patients. Arch. Med. Sci.","DOI":"10.5114\/aoms.2020.98168"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"103382","DOI":"10.1016\/j.isci.2021.103382","article-title":"Recombinant human GLP-1 beinaglutide regulates lipid metabolism of adipose tissues in diet-induced obese mice","volume":"24","author":"Zhang","year":"2021","journal-title":"iScience"},{"key":"ref_84","first-page":"421","article-title":"Effect of beinaglutide treatment on weight loss in Chinese patients with type 2 diabetes mellitus and overweight\/obesity","volume":"65","author":"Wang","year":"2021","journal-title":"Arch. Endocrinol. Metab."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1007\/s40265-014-0320-7","article-title":"Dulaglutide: First global approval","volume":"74","author":"Sanford","year":"2014","journal-title":"Drugs"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1002\/dmrr.2810","article-title":"Efficacy and safety of dulaglutide in the treatment of type 2 diabetes: A comprehensive review of the dulaglutide clinical data focusing on the AWARD phase 3 clinical trial program","volume":"32","author":"Jendle","year":"2016","journal-title":"Diabetes Metab. Res. Rev."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s40265-020-01260-9","article-title":"Dulaglutide: A Review in Type 2 Diabetes","volume":"80","author":"Scott","year":"2020","journal-title":"Drugs"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"765","DOI":"10.2337\/dc20-1473","article-title":"Efficacy and Safety of Dulaglutide 3.0 mg and 4.5 mg Versus Dulaglutide 1.5 mg in Metformin-Treated Patients with Type 2 Diabetes in a Randomized Controlled Trial (AWARD-11)","volume":"44","author":"Frias","year":"2021","journal-title":"Diabetes Care"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.diabet.2017.10.007","article-title":"Durability of protective effect of dulaglutide on pancreatic \u03b2-cells in diabetic mice: GLP-1 receptor expression is not reduced despite long-term dulaglutide exposure","volume":"44","author":"Kimura","year":"2018","journal-title":"Diabetes Metab."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"105649","DOI":"10.1016\/j.intimp.2019.05.034","article-title":"Dulaglutide mitigates inflammatory response in fibroblast-like synoviocytes","volume":"74","author":"Zheng","year":"2019","journal-title":"Int. Immunopharmacol."},{"key":"ref_91","doi-asserted-by":"crossref","unstructured":"Yifan, W., Yixiang, W., Yang, W., and Yiqing, W. (2023). Dulaglutide Ameliorates Intrauterine Adhesion by Suppressing Inflammation and Epithelial\u2013Mesenchymal Transition Via Inhibiting the TGF-\u03b2\/Smad2 Signaling Pathway. Pharmaceuticals, 16.","DOI":"10.3390\/ph16070964"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"175730","DOI":"10.1016\/j.ejphar.2023.175730","article-title":"Dulaglutide provides protection against sepsis-induced lung injury in mice by inhibiting inflammation and apoptosis","volume":"949","author":"Wang","year":"2023","journal-title":"Eur. J. Pharmacol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12933-023-01775-x","article-title":"Weight-dependent and weight-independent effects of dulaglutide on blood pressure in patients with type 2 diabetes","volume":"22","author":"Ferdinand","year":"2023","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1186\/s12933-021-01386-4","article-title":"Exploring potential mediators of the cardiovascular benefit of dulaglutide in type 2 diabetes patients in REWIND","volume":"20","author":"Konig","year":"2021","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.2337\/dc22-2397","article-title":"Biomarker Changes Associated with Both Dulaglutide and Cardiovascular Events in the REWIND Randomized Controlled Trial: A Nested Case-Control Post Hoc Analysis","volume":"46","author":"Hertzel","year":"2023","journal-title":"Diabetes Care"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","article-title":"Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): A double-blind, randomised placebo-controlled trial","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.abb.2019.07.008","article-title":"Dulaglutide inhibits high glucose- induced endothelial dysfunction and NLRP3 inflammasome activation","volume":"671","author":"Luo","year":"2019","journal-title":"Arch. Biochem. Biophys."},{"key":"ref_98","doi-asserted-by":"crossref","unstructured":"Mei, X., Li, Y., Wu, J., Liao, L., Lu, D., Qiu, P., Yang, H.-l., Tang, M.-w., Liang, X.-y., and Liu, D. (2024). Dulaglutide restores endothelial progenitor cell levels in diabetic mice and mitigates high glucose-induced endothelial injury through SIRT1-mediated mitochondrial fission. Biochem. Biophys. Res. Commun., 716.","DOI":"10.1016\/j.bbrc.2024.150002"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s40265-018-0871-0","article-title":"Semaglutide: First Global Approval","volume":"78","author":"Dhillon","year":"2018","journal-title":"Drugs"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1089\/dia.2019.0185","article-title":"Oral Semaglutide: A Review of the First Oral Glucagon-Like Peptide 1 Receptor Agonist","volume":"22","author":"Bucheit","year":"2019","journal-title":"Diabetes Technol. Ther."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1080\/14656566.2018.1552258","article-title":"Oral semaglutide for the treatment of type 2 diabetes","volume":"20","author":"Hedrington","year":"2018","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"107520","DOI":"10.1016\/j.jdiacomp.2019.107520","article-title":"Oral semaglutide in type 2 diabetes","volume":"34","author":"Anderson","year":"2020","journal-title":"J. Diabetes Its Complicat."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1002\/cpdd.938","article-title":"Relationship Between Oral Semaglutide Tablet Erosion and Pharmacokinetics: A Pharmacoscintigraphic Study","volume":"10","author":"Baekdal","year":"2021","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1007\/s13300-021-01078-y","article-title":"Effect of Various Dosing Conditions on the Pharmacokinetics of Oral Semaglutide, a Human Glucagon-Like Peptide-1 Analogue in a Tablet Formulation","volume":"12","author":"Breitschaft","year":"2021","journal-title":"Diabetes Ther."},{"key":"ref_105","doi-asserted-by":"crossref","unstructured":"Gallwitz, B., and Giorgino, F. (2021). Clinical Perspectives on the Use of Subcutaneous and Oral Formulations of Semaglutide. Front. Endocrinol., 12.","DOI":"10.3389\/fendo.2021.645507"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"110605","DOI":"10.1016\/j.diabres.2023.110605","article-title":"Efficacy and safety of oral semaglutide in type 2 diabetes mellitus: A systematic review and meta-analysis","volume":"198","author":"Li","year":"2023","journal-title":"Diabetes Res. Clin. Pract."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1001\/jama.2017.14752","article-title":"Effect of Oral Semaglutide Compared with Placebo and Subcutaneous Semaglutide on Glycemic Control in Patients with Type 2 Diabetes","volume":"318","author":"Davies","year":"2017","journal-title":"JAMA"},{"key":"ref_108","doi-asserted-by":"crossref","unstructured":"Smits, M.M., and Van Raalte, D.H. (2021). Safety of Semaglutide. Front. Endocrinol., 12.","DOI":"10.3389\/fendo.2021.645563"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"86","DOI":"10.2337\/db23-86-LB","article-title":"86-LB: Real-World Impact of Oral Semaglutide on Glycemic Control and Weight Outcomes in Type 2 Diabetes (RELATE\u2013Oral Semaglutide)","volume":"72","author":"James","year":"2023","journal-title":"Diabetes"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"87","DOI":"10.2337\/db23-87-LB","article-title":"87-LB: Real-World Impact of Once-Weekly Injectable Semaglutide on Glycemic Control and Weight Outcomes in Type 2 Diabetes (RELATE-OW Injectable Semaglutide)","volume":"72","author":"James","year":"2023","journal-title":"Diabetes"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1111\/dom.14990","article-title":"Safety and tolerability of semaglutide across the SUSTAIN and PIONEER phase IIIa clinical trial programmes","volume":"25","author":"Aroda","year":"2023","journal-title":"Diabetes Obes. Metab."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/S0140-6736(23)01479-4","article-title":"Oral semaglutide: An OASIS from injectables","volume":"402","author":"Priya","year":"2023","journal-title":"Lancet"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.2147\/DMSO.S385196","article-title":"A Peptide in a Pill\u2014Oral Semaglutide in the Management of Type 2 Diabetes","volume":"16","author":"Selvarajan","year":"2023","journal-title":"Diabetes Metab. Syndr. Obes. Targets Ther."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1038\/s41569-023-00935-6","article-title":"Semaglutide is beneficial in patients with HFpEF and obesity","volume":"20","author":"Irene","year":"2023","journal-title":"Nat. Rev. Cardiol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1016\/j.jacc.2023.09.811","article-title":"Semaglutide Effects According to Ejection Fraction in Heart Failure with Preserved Ejection Fraction and Obesity","volume":"82","author":"Javed","year":"2023","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_116","doi-asserted-by":"crossref","unstructured":"Li, X., Luo, W., Tang, Y., Wu, J., Zhang, J., Chen, S., Zhou, L., Tao, Y., Tang, Y., and Wang, F. (2024). Semaglutide attenuates doxorubicin-induced cardiotoxicity by ameliorating BNIP3-Mediated mitochondrial dysfunction. Redox Biol., 72.","DOI":"10.1016\/j.redox.2024.103129"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1007\/s12020-024-03823-2","article-title":"Semaglutide attenuates pathological electrophysiological remodeling in diabetic cardiomyopathy via restoring Cx43 expression","volume":"84","author":"Yan","year":"2024","journal-title":"Endocrine"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1016\/j.jacbts.2023.05.012","article-title":"The Cardioprotective Effects of Semaglutide Exceed Those of Dietary Weight Loss in Mice with HFpEF","volume":"8","author":"Coenraad","year":"2023","journal-title":"JACC Basic Transl. Sci."},{"key":"ref_119","first-page":"869","article-title":"Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity","volume":"115","author":"Mikhail","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"gfad063c_6005","DOI":"10.1093\/ndt\/gfad063c_6005","article-title":"#6005 Comparison of Semaglutide Oral vs Subcutaneous in Chronic Kidney Disease (CKD)","volume":"38","author":"Paula","year":"2023","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"3893","DOI":"10.2147\/DDDT.S383537","article-title":"Metabolomics Provides Insights into Renoprotective Effects of Semaglutide in Obese Mice","volume":"16","author":"Chen","year":"2022","journal-title":"Drug Des. Dev. Ther."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"gfad063c_5826","DOI":"10.1093\/ndt\/gfad063c_5826","article-title":"#5826 Nephroprotective Effects of Semaglutide in a Mouse Model of Hypertension-Accelerated Diabetic Kidney Disease","volume":"38","author":"Michael","year":"2023","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1007\/s40265-022-01746-8","article-title":"Tirzepatide: First Approval","volume":"82","author":"Syed","year":"2022","journal-title":"Drugs"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"170183","DOI":"10.1016\/j.peptides.2019.170183","article-title":"Evaluation of the incretin effect in humans using GIP and GLP-1 receptor antagonists","volume":"125","author":"Gasbjerg","year":"2019","journal-title":"Peptides"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"5636499","DOI":"10.1155\/2022\/5636499","article-title":"Regulation of Glucose Insulinotropic Peptide and Intestinal Glucose Transporters in the Diet-Induced Obese Mouse","volume":"2022","author":"Rhodes","year":"2022","journal-title":"J. Diabetes Res."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"4897","DOI":"10.1210\/jc.2003-030738","article-title":"The pathophysiology of diabetes involves a defective amplification of the late-phase insulin response to glucose by glucose-dependent insulinotropic polypeptide-regardless of etiology and phenotype","volume":"88","author":"Knop","year":"2003","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"101090","DOI":"10.1016\/j.molmet.2020.101090","article-title":"Glucagon-like Peptide-1 Receptor co-agonists for the treatment of metabolic disease","volume":"46","author":"Baggio","year":"2020","journal-title":"Mol. Metab."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"e2710","DOI":"10.1210\/clinem\/dgaa327","article-title":"GIP as a Therapeutic Target in Diabetes and Obesity: Insight from Incretin Co-agonists","volume":"105","author":"Holst","year":"2020","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1210\/clinem\/dgaa863","article-title":"Dual GIP and GLP-1 Receptor Agonist Tirzepatide Improves Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes","volume":"106","author":"Thomas","year":"2020","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.molmet.2018.09.009","article-title":"LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept","volume":"18","author":"Coskun","year":"2018","journal-title":"Mol. Metab."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/S2213-8587(22)00085-7","article-title":"Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: A multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial","volume":"10","author":"Heise","year":"2022","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1038\/s42255-023-00811-0","article-title":"The incretin co-agonist tirzepatide requires GIPR for hormone secretion from human islets","volume":"5","author":"El","year":"2023","journal-title":"Nat. Metab."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/S0140-6736(23)01200-X","article-title":"Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): A double-blind, randomised, multicentre, placebo-controlled, phase 3 trial","volume":"402","author":"Garvey","year":"2023","journal-title":"Lancet"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.bbrc.2017.06.031","article-title":"Central administration of GLP-1 and GIP decreases feeding in mice","volume":"490","author":"NamKoong","year":"2017","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.cmet.2021.01.015","article-title":"The glucose-dependent insulinotropic polypeptide (GIP) regulates body weight and food intake via CNS-GIPR signaling","volume":"33","author":"Zhang","year":"2021","journal-title":"Cell Metab."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/S2213-8587(22)00243-1","article-title":"Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: Post-hoc analysis of an open-label, randomised, phase 3 trial","volume":"10","author":"Heerspink","year":"2022","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"A13426","DOI":"10.1161\/circ.142.suppl_3.13426","article-title":"Abstract 13426: The Dual GIP\/GLP-1 Receptor Agonist Tirzepatide Improves Cardiovascular Risk Protein Biomarkers in Patients with Type 2 Diabetes","volume":"142","author":"Wilson","year":"2020","journal-title":"Circulation"},{"key":"ref_138","doi-asserted-by":"crossref","unstructured":"Lian, J., and Fu, J. (2021). Pioglitazone for NAFLD Patients with Prediabetes or Type 2 Diabetes Mellitus: A Meta-analysis. Front. Endocrinol., 12.","DOI":"10.3389\/fendo.2021.615409"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"4781","DOI":"10.2174\/0109298673251493231011192520","article-title":"SGLT-2 Inhibitors: The Next-generation Treatment for Type 2 Diabetes Mellitus","volume":"31","author":"Lukic","year":"2023","journal-title":"Curr. Med. Chem."},{"key":"ref_140","first-page":"744","article-title":"Repaglinide: A review of its use in type 2 diabetes mellitus (vol 72, pg 249, 2012)","volume":"72","author":"Repaglinide","year":"2012","journal-title":"Drugs"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1080\/14656566.2021.1999413","article-title":"The role of sulfonylureas in the treatment of type 2 diabetes","volume":"23","author":"Tomlinson","year":"2022","journal-title":"Expert Opin. Pharmaco."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"108590","DOI":"10.1016\/j.jdiacomp.2023.108590","article-title":"Dipeptidyl peptidase-4 inhibitor-related renal disease","volume":"37","author":"Suenaga","year":"2023","journal-title":"J. Diabetes Complicat."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1007\/s00125-017-4336-x","article-title":"Metformin: Clinical use in type 2 diabetes","volume":"60","author":"Inzucchi","year":"2017","journal-title":"Diabetologia"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"115119","DOI":"10.1016\/j.ejmech.2023.115119","article-title":"Synthetic \u03b1-glucosidase inhibitors as promising anti-diabetic agents: Recent developments and future challenges","volume":"249","author":"Mushtaq","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"29959","DOI":"10.1073\/pnas.2014879117","article-title":"Structural basis for GLP-1 receptor activation by LY3502970, an orally active nonpeptide agonist [Pharmacology]","volume":"117","author":"Kawai","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/S0140-6736(23)01302-8","article-title":"Efficacy and safety of oral orforglipron in patients with type 2 diabetes: A multicentre, randomised, dose-response, phase 2 study","volume":"402","author":"Frias","year":"2023","journal-title":"Lancet"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"339","DOI":"10.2337\/db22-339-OR","article-title":"339-OR: Oral Small-Molecule GLP-1R Agonist Danuglipron Robustly Reduces Plasma Glucose and Body Weight after Eight Weeks in Japanese Adults with Type 2 Diabetes Mellitus","volume":"71","author":"Ono","year":"2022","journal-title":"Diabetes"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1038\/s41591-021-01391-w","article-title":"Danuglipron (PF-06882961) in type 2 diabetes: A randomized, placebo-controlled, multiple ascending-dose phase 1 trial","volume":"27","author":"Saxena","year":"2021","journal-title":"Nat. Med."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"e2314493","DOI":"10.1001\/jamanetworkopen.2023.14493","article-title":"Efficacy and Safety of Oral Small Molecule Glucagon-Like Peptide 1 Receptor Agonist Danuglipron for Glycemic Control Among Patients with Type 2 Diabetes: A Randomized Clinical Trial","volume":"6","author":"Saxena","year":"2023","journal-title":"JAMA Netw. Open"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1111\/dom.15383","article-title":"Safety, pharmacokinetics and pharmacodynamics of HRS-7535, a novel oral small molecule glucagon-like peptide-1 receptor agonist, in healthy participants: A phase 1, randomized, double-blind, placebo-controlled, single- and multiple-ascending dose, and food effect trial","volume":"26","author":"Wu","year":"2023","journal-title":"Diabetes Obes. Metab."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"174635","DOI":"10.1016\/j.ejphar.2021.174635","article-title":"An oral GLP-1 and GIP dual receptor agonist improves metabolic disorders in high fat-fed mice","volume":"914","author":"Ma","year":"2021","journal-title":"Eur. J. Pharmacol."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.apsb.2018.06.005","article-title":"Adapting liposomes for oral drug delivery","volume":"9","author":"He","year":"2019","journal-title":"Acta Pharm. Sin. B"},{"key":"ref_153","doi-asserted-by":"crossref","unstructured":"He, Y., Huang, Y., Xu, H., Yang, X., Liu, N., Xu, Y., Ma, R., Zhai, J., Ma, Y., and Guan, S. (2022). Aptamer-modified M cell targeting liposomes for oral delivery of macromolecules. Colloids Surf. B Biointerfaces, 222.","DOI":"10.1016\/j.colsurfb.2022.113109"},{"key":"ref_154","doi-asserted-by":"crossref","unstructured":"Cui, J., Wen, Z., Zhang, W., and Wu, W. (2022). Recent Advances in Oral Peptide or Protein-Based Drug Liposomes. Pharmaceuticals, 15.","DOI":"10.3390\/ph15091072"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/j.addr.2012.10.007","article-title":"Nanoparticles for oral delivery: Targeted nanoparticles with peptidic ligands for oral protein delivery","volume":"65","author":"Yun","year":"2013","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"e1801123","DOI":"10.1002\/adhm.201801123","article-title":"Protein Corona Liposomes Achieve Efficient Oral Insulin Delivery by Overcoming Mucus and Epithelial Barriers","volume":"8","author":"Wang","year":"2018","journal-title":"Adv. Healthc. Mater."},{"key":"ref_157","doi-asserted-by":"crossref","unstructured":"Ding, R., Zhao, Z., He, J., Tao, Y., Zhang, H., Yuan, R., Sun, K., and Shi, Y. (2023). Preparation, Drug Distribution, and In Vivo Evaluation of the Safety of Protein Corona Liposomes for Liraglutide Delivery. Nanomaterials, 13.","DOI":"10.3390\/nano13030540"},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/S0167-7799(01)01739-5","article-title":"The \u2018biodrug\u2019 concept: An innovative approach to therapy","volume":"19","author":"Blanquet","year":"2001","journal-title":"Trends Biotechnol."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1080\/10717544.2018.1551439","article-title":"Rhodotorula glutinis as a living cell liposome to deliver polypeptide drugs in vivo","volume":"26","author":"Fei","year":"2019","journal-title":"Drug Deliv."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.jconrel.2022.05.027","article-title":"Exosomes: Large-scale production, isolation, drug loading efficiency, and biodistribution and uptake","volume":"347","author":"Oncel","year":"2022","journal-title":"J. Control. Release"},{"key":"ref_161","doi-asserted-by":"crossref","unstructured":"Zhong, J., Xia, B., Shan, S., Zheng, A., Zhang, S., Chen, J., and Liang, X.-J. (2021). High-quality milk exosomes as oral drug delivery system. Biomaterials, 277.","DOI":"10.1016\/j.biomaterials.2021.121126"},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1016\/j.apsb.2021.12.015","article-title":"Milk-derived exosomes exhibit versatile effects for improved oral drug delivery","volume":"12","author":"Wu","year":"2021","journal-title":"Acta Pharm. Sin. B"},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"21091","DOI":"10.1021\/acsnano.4c02560","article-title":"Milk Exosome\u2013Liposome Hybrid Vesicles with Self-Adapting Surface Properties Overcome the Sequential Absorption Barriers for Oral Delivery of Peptides","volume":"18","author":"Xiao","year":"2024","journal-title":"ACS Nano"},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"e2307618","DOI":"10.1002\/smll.202307618","article-title":"Comparative Analysis of PEG-Free and PEG-Based Self-Emulsifying Drug Delivery Systems for Enhanced Oral Bioavailability of Therapeutic (Poly) Peptides","volume":"20","author":"Haddadzadegan","year":"2024","journal-title":"Small"},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.addr.2018.07.001","article-title":"SEDDS: A game changing approach for the oral administration of hydrophilic macromolecular drugs","volume":"142","author":"Mahmood","year":"2018","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.jconrel.2018.03.018","article-title":"In vivo evaluation of an oral self-emulsifying drug delivery system (SEDDS) for exenatide","volume":"277","author":"Menzel","year":"2018","journal-title":"J. Control. Release"},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"5032","DOI":"10.1021\/acsbiomaterials.0c00637","article-title":"The Effect of Counterions in Hydrophobic Ion Pairs on Oral Bioavailability of Exenatide","volume":"6","author":"Phan","year":"2020","journal-title":"ACS Biomater. Sci. Eng."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.ejpb.2023.09.003","article-title":"Double layer spherical nanoparticles with hyaluronic acid coating to enhance oral delivery of exenatide in T2DM rats","volume":"191","author":"Lu","year":"2023","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.jconrel.2021.08.013","article-title":"Solid self emulsifying drug delivery system: Superior mode for oral delivery of hydrophobic cargos","volume":"337","author":"Maji","year":"2021","journal-title":"J. Control. Release"},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"123899","DOI":"10.1016\/j.ijpharm.2024.123899","article-title":"Novel solid self-emulsifying drug delivery system to enhance oral bioavailability of cabazitaxel","volume":"654","author":"Sun","year":"2024","journal-title":"Int. J. Pharm."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"120838","DOI":"10.1016\/j.carbpol.2023.120838","article-title":"Progress and prospects of polysaccharide-based nanocarriers for oral delivery of proteins\/peptides","volume":"312","author":"Yuan","year":"2023","journal-title":"Carbohydr. Polym."},{"key":"ref_172","doi-asserted-by":"crossref","unstructured":"Wang, Y., Li, H., Rasool, A., Wang, H., Manzoor, R., and Zhang, G. (2024). Polymeric nanoparticles (PNPs) for oral delivery of insulin. J. Nanobiotechnol., 22.","DOI":"10.1186\/s12951-023-02253-y"},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.foodhyd.2017.05.043","article-title":"Mucoadhesion: A food perspective","volume":"72","author":"Sarah","year":"2017","journal-title":"Food Hydrocoll."},{"key":"ref_174","doi-asserted-by":"crossref","unstructured":"Yang, J.-M., Wu, L.-J., Lin, M.-T., Lu, Y.-Y., Wang, T.-T., Han, M., Zhang, B., and Xu, D.-H. (2022). Construction and Evaluation of Chitosan-Based Nanoparticles for Oral Administration of Exenatide in Type 2 Diabetic Rats. Polymers, 14.","DOI":"10.3390\/polym14112181"},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"104685","DOI":"10.1016\/j.phrs.2020.104685","article-title":"Oral administration of protein nanoparticles: An emerging route to disease treatment","volume":"158","author":"Sadeghi","year":"2020","journal-title":"Pharmacol. Res."},{"key":"ref_176","doi-asserted-by":"crossref","unstructured":"Bao, X., Qian, K., Xu, M., Chen, Y., Wang, H., Pan, T., Wang, Z., Yao, P., and Lin, L. (2023). Intestinal epithelium penetration of liraglutide via cholic acid pre-complexation and zein\/rhamnolipids nanocomposite delivery. J. Nanobiotechnol., 21.","DOI":"10.1186\/s12951-022-01743-9"},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"17073","DOI":"10.1021\/acs.chemrev.2c00344","article-title":"Zwitterionic Biomaterials","volume":"122","author":"Li","year":"2022","journal-title":"Chem. Rev."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"105437","DOI":"10.1016\/j.jddst.2024.105437","article-title":"Sulfobetaine modification of poly (D, L-lactide-co-glycolic acid) nanoparticles enhances mucus permeability and improves bioavailability of orally delivered liraglutide","volume":"93","author":"Zhao","year":"2024","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"15252","DOI":"10.1039\/C7NR05762H","article-title":"Evaluation of mesoporous silica nanoparticles for oral drug delivery\u2014Current status and perspective of MSNs drug carriers","volume":"9","author":"Florek","year":"2017","journal-title":"Nanoscale"},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.jconrel.2020.07.021","article-title":"Silica nanoparticles: A promising platform for enhanced oral delivery of macromolecules","volume":"326","author":"Abeer","year":"2020","journal-title":"J. Control. Release"},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"e20430","DOI":"10.1016\/j.heliyon.2023.e20430","article-title":"Exploring mesoporous silica nanoparticles as oral insulin carriers: In-silico and in vivo evaluation","volume":"9","author":"Ehsan","year":"2023","journal-title":"Heliyon"},{"key":"ref_182","doi-asserted-by":"crossref","unstructured":"Abeer, M.M., Meka, A.K., Pujara, N., Kumeria, T., Strounina, E., Nunes, R., Costa, A., Sarmento, B., Hasnain, S.Z., and Ross, B.P. (2019). Rationally Designed Dendritic Silica Nanoparticles for Oral Delivery of Exenatide. Pharmaceutics, 11.","DOI":"10.3390\/pharmaceutics11080418"},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"nwaa221","DOI":"10.1093\/nsr\/nwaa221","article-title":"Multimodal channel cancer chemotherapy by 2D functional gadolinium metal\u2013organic framework","volume":"8","author":"Xia","year":"2020","journal-title":"Natl. Sci. Rev."},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1039\/D1TB02518J","article-title":"Advances in antitumor nanomedicine based on functional metal\u2013organic frameworks beyond drug carriers","volume":"10","author":"Wei","year":"2021","journal-title":"J. Mater. Chem. B"},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"e202300018","DOI":"10.1002\/tcr.202300018","article-title":"Metal-Organic Frameworks Nanocarriers for Functional Nucleic Acid Delivery in Biomedical Applications","volume":"23","author":"He","year":"2023","journal-title":"Chem. Rec."},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"eabm4677","DOI":"10.1126\/sciadv.abm4677","article-title":"Efficient oral insulin delivery enabled by transferrin-coated acid-resistant metal-organic framework nanoparticles","volume":"8","author":"Zou","year":"2022","journal-title":"Sci. Adv."},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"168","DOI":"10.2174\/1567201820666221220103013","article-title":"Recent Excavation of Nanoethosomes in Current Drug Delivery","volume":"21","author":"Agrawal","year":"2024","journal-title":"Curr. Drug Deliv."}],"container-title":["Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4923\/16\/11\/1353\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:18:47Z","timestamp":1760113127000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4923\/16\/11\/1353"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,23]]},"references-count":187,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2024,11]]}},"alternative-id":["pharmaceutics16111353"],"URL":"https:\/\/doi.org\/10.3390\/pharmaceutics16111353","relation":{},"ISSN":["1999-4923"],"issn-type":[{"value":"1999-4923","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,23]]}}}